Skip to main content

Table 2 Correlations between expression of CALD1 and clinicopathologic characteristics in OC from TCGA cohort (n = 379)

From: Upregulation of CALD1 predicted a poor prognosis for platinum-treated ovarian cancer and revealed it as a potential therapeutic resistance target

Clinical features

Case

CALD1 level

(mean ± SD)

p value

Age at diagnosis (years)

 ≤ 60

208

4.2896 ± 0.8494

0.474

 > 60

171

4.2229 ± 0.9611

Clinical stage

 I-II

24

3.8833 ± 0.6890

0.034*

 III-IV

352

4.2831 ± 0.9046

 Unknown

3

  

Grade

 G1-G2

46

4.2779 ± 0.9729

0.888

 G3-G4

323

4.2577 ± 0.8960

 Unknown

10

  

Longest dimension

 ≤ 1

84

4.2222 ± 0.9496

0.445

 1–2

188

4.2975 ± 0.9387

 ≥ 2

43

4.4390 ± 0.6436

 Unknown

64

  

Anatomic neoplasm subdivision

 Bilateral

255

4.2740 ± 0.9351

0.446

 Unilaterral

102

4.1931 ± 0.8228

 Unknown

22

  

Residual tumor

 0

67

4.1610 ± 0.7174

0.706

 1–10 mm

171

4.3079 ± 0.9005

 11–20 mm

27

4.2219 ± 0.6972

 > 20 mm

70

4.2757 ± 1.0448

 Unknown

44

  

Lymphatic invasion

 Yes

101

4.2238 ± 0.9285

0.736

 No

48

4.1707 ± 0.8225

 Unknown

230

  

Venous invasion

 Yes

32

4.2038 ± 0.6325

 < 0.001***

 No

35

3.5051 ± 0.4561

 Unknown

312

  
  1. SD Standard Deviation
  2. Note: * P < 0.05, *** P < 0.001